Triple-negative receptor status and prognosis in the NCIC CTG MA. 21 adjuvant breast cancer trial

摘要: 550 Background: Triple-negative breast tumors which are negative for ER, PR, and HER2-neu receptors by immunohistochemistry associated with a poor prognosis. The MA.21 trial compared 3 adjuvant chemotherapy regimens after surgery in pre- or early menopausal women 60 years younger cancer (Proceedings ASCO 2007, 25, 550). This analysis explored the outcome of triple-negative subset patients to nontriple negatives respect relapse-free survival (RFS). Methods: Women axillary node-positive high-risk node-negative were randomized cyclophosphamide, epirubicin, 5FU (CEF), dose-dense epirubicin cyclophosphamide plus filgrastim followed paclitaxel (EC/T) doxorubicin (AC/T), six months. ER status was known stratification factor all patients. Median follow-up 30.4 months 261 recurrences. Characteristics without knowledge triple-negative...